1. v Global Liver Diseases Therapeutics Market Size and Share, Growth, Market Price, Analysis, Forecast and Overview 2015 - 2019 www.hexareports.com Category: Pharmaceutical

2. Report Overview Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment. The liver diseases caused by viral infections, alcoholism, obesity, diabetes, among many other reasons. Some of the diseases are not curable such as liver cirrhosis or non-alcoholic fatty liver disease, and are usually not diagnosed early. This leads to the substantial damage of the liver, which proves to be life-threatening. Some types of hepatitis are preventable or treatable by using vaccines and indicated drugs. Technavio's analysts forecast the global liver diseases therapeutics market to grow at a CAGR of 15.61% over the period 2014-2019. www.hexareports.com

3. Covered in this report This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases. Based on disease indication, the market is segmented as follows: Non-alcoholic fatty liver disease (includes non-alcoholic steatohepatitis) Liver cirrhosis Liver cancer Hepatitis (Hepatitis A, B, and C) This report includes a discussion of the market in the following three regions: Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Easternand African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India. www.hexareports.com

4. Other prominent vendors  AbbVie  Achillion Pharmaceuticals  Advinus  Angion Biomedica  AstraZeneca  Bayer  BiOrion  Boehringer Ingelheim  Bristol-Myers Squibb  Celsion  Conatus  Digna Biotech  Dynavax Technologies  Eli Lilly  Galectin Therapeutics  LG Life Sciences www.hexareports.com

5. Key market Key market driver Increased prevalence of liver diseases For a full, detailed list, view our report Key market challenge Multiple patent expiries For a full, detailed list, view our report Key market trend Growing public awareness For a full, detailed list, view our report Key questions answered in this report What will the market size be in 2019 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? www.hexareports.com

6. Stay With US Global Head Quarters Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, ‏United States. E-mail : sales@hexareports.com Telephone Direct : 1-800-489-3075 Thank You! For More Details http://www.hexareports.com/report/global-liver-diseases-therapeutics- market/details